Fosamax and Osteonecrosis of the Jaw: How Alendronate Triggers Jawbone Necrosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Occupational Exposure Concerns

The legacy domain of general health and science information has historically provided broad, accessible overviews of medical conditions and therapeutic interventions. Within this context, public awareness of medication side effects has been a key focus, often drawing on structured data from academic databases and public health registries. This foundation has enabled the identification of emerging safety signals, such as those related to long-term bisphosphonate use. Transitioning from this general health perspective to a more specialized occupational concern, the focus narrows to the specific exposure context of Fosamax (alendronate) in mass production environments. In industrial settings, workers may encounter the active pharmaceutical ingredient during manufacturing, formulation, or packaging processes. This occupational exposure differs from patient consumption, as it involves repeated, potentially higher-concentration contact via inhalation or dermal routes. The concern shifts from patient-level risk communication to workplace hazard assessment, where the primary question is how chronic, low-level exposure to Fosamax in production facilities might contribute to adverse outcomes, including osteonecrosis of the jaw. This pivot requires examining the pathophysiological pathways triggered by alendronate at the cellular level, without making disease-specific mechanistic claims, but rather framing the inquiry within industrial hygiene and toxicology. The transition thus moves from general health literacy to a targeted investigation of occupational exposure risks in pharmaceutical manufacturing.

Bridging to Pathophysiology: How Fosamax Affects Jawbone Remodeling

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a serious adverse event: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology linking Fosamax to ONJ involves the drug's potent suppression of bone remodeling. Bisphosphonates like alendronate accumulate in the jawbone, which has a high rate of turnover due to constant mechanical stress from chewing and the presence of teeth. This accumulation leads to prolonged inhibition of osteoclast activity, impairing the normal repair and renewal of bone tissue. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially predisposing it to necrosis.

Clinical Presentation and Risk Factors for ONJ

The clinical presentation of ONJ includes pain, swelling, infection, and exposed bone in the jaw. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate use being a key factor. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients who developed symptoms had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation Considerations and Evidence for a Causal Link

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the increased risk with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1) and the presence of known risk factors such as dental procedures and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1) are important considerations. The multiscale characterization of jawbone treated with osteoporosis therapeutic agents provides a biological basis for understanding how bisphosphonates may contribute to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) suppresses bone remodeling by inhibiting osteoclast activity. It accumulates in the jawbone, which has high turnover, leading to prolonged inhibition of bone repair and renewal. This can result in non-healing bone lesions characteristic of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ symptoms appear?

Symptoms can appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.